Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

SHOCKING: Honasa - What They Never Told You

Mamaearth parent Honasa Consumer targets Rs 5,500 cr revenue by FY31

Honasa Consumer expects revenue to double to Rs 5,550 crore by FY31. The company also targets an Ebitda margin of 15 percent during the same period. Growth will focus on existing popular categories and expanding into new ones. Mamaearth, the flagship brand, is showing renewed growth in key segments. Honasa…

The Economic Times

F&O Talk: Nifty consolidation to continue says Sudeep Shah; gives Tata Motors, Lenskart, Honasa strategy

Nifty remains range-bound amid falling volatility, with 24,200–24,150 as key support and 24,550–24,600 as resistance. Options data shows strong Put writing, suggesting limited downside. Analysts prefer PSU banks, while defence, auto and chemicals remain technically strong.

The Economic Times

Honasa Consumer shares jump 4% after record Q1; Jefferies, Emkay forecast strong upside

Honasa Consumer’s shares rose after Q1FY27 PAT surged 116.5% YoY to a record ₹90 crore, while revenue grew 27% to ₹756 crore and EBITDA jumped 141% to ₹110 crore.

The Economic Times

From analysis to the latest developments in health,
read the most diverse news in one place.

Honasa Consumer Q1 Results: Mamaearth parent posts record profit of Rs 90 crore; revenue up 27% YoY

Honasa Consumer, the parent of Mamaearth, reported a record Rs 90 crore consolidated PAT in Q1FY27, up 116.5% YoY. Revenue rose 27% to Rs 756 crore, while EBITDA surged 141% to Rs 110 crore. Strong growth across focus categories, brands and offline channels supported the company’s performance.

The Economic Times

India's growth story, not AI trade reversal, will drive foreign flows: Sameer Dalal

India's economic strength, not AI's decline, will drive foreign capital inflows, according to Sameer Dalal. He believes AI's market correction is temporary, while India's improving fundamentals, including falling crude prices and monsoon progress, position it for growth. Dalal remains bullish on pharma and cement sectors, sees achievable targets for Tata…

The Economic Times

Honasa Consumer enters nutraceuticals segment; to acquires 58 pc stake in Fluence Pharma

Honasa Consumer, parent of Mamaearth, is acquiring a 58% stake in nutraceuticals firm Fluence Pharma for Rs 135 crore, marking its entry into the health and wellness supplements market. This strategic move aims to leverage Fluence's patented technology and dermatologist network to expand Honasa's 'inside-out' beauty solutions. The acquisition is…

The Economic Times

Honasa Consumer to acquire majority stake in Fluence Pharma at Rs 135-crore valuation

Honasa Consumer has secured a majority stake in Mumbai's hair therapy brand Fluence Pharma for Rs 135 crore. This move marks the company's second acquisition in under a year, following its purchase of Reginald Men in December.

The Economic Times

Read news from The Economist, FT, and more,
with one subscription

Fable 5's cost challenge; Opendoor's India exit

Anthropic's Fable 5 could rewrite how IT works, but the price tag and performance quirks raise hard questions. This and more in today’s ETtech Top 5.

The Economic Times

Honasa shares jump 6% on Rs 5,500 crore revenue target by FY31. What is Goldman Sachs saying?

Honasa Consumer shares surged after the company outlined a revenue target of ₹5,500 crore by FY31. The guidance implies an annual growth rate of around 18% between FY26 and FY31. Growth is expected to be led by Mamaearth, with revenue projected to exceed ₹2,000 crore, while The Derma Co is…

The Economic Times

Nykaa vs Honasa: Which stock should you buy after Q4 earnings? Here’s what experts say

Nykaa and Mamaearth parent companies saw share surges Friday. Both beauty firms reported strong profit jumps. International brokerages issued bullish calls. Nykaa's parent, FSN E-Commerce Ventures, posted a 286% profit increase. Mamaearth's parent, Honasa Consumer, reported a 177% profit jump. Analysts suggest patience for fresh investments in these stocks.

The Economic Times

Rahul Shah bullish on pharma, sees Sun Pharma and Aurobindo as key large-cap plays

Indian equity markets show a mixed but improving consumption trend, with selective FMCG and premium retail outperforming. Page Industries is highlighted as a strong recovery story, while Nykaa and Honasa are viewed cautiously. The pharma sector continues its outperformance, with Sun Pharma and Aurobindo Pharma looking attractive.

The Economic Times

Can Honasa shares rally up to 57% after strong Q4 show? Jefferies, CLSA & two other brokerages weigh in

Honasa Consumer shares surged over 11% on Friday after a strong Q4 FY26 performance, with brokerages including Jefferies, CLSA, ICICI Securities and JM Financial turning more optimistic. Jefferies sees up to 57% upside, citing robust multi-channel growth, improving margins and stronger execution, while other brokerages also highlight rising traction across…

The Economic Times

Honasa Consumer shares zoom 11% on robust Q4. Jefferies, CLSA see more room to run

Honasa Consumer, Mamaearth's parent company, saw its shares surge after reporting a 177% year-on-year jump in net profit to Rs 69 crore for Q4 FY26. Revenue also climbed over 23% to Rs 657 crore, with EBITDA soaring 186%. Analysts from CLSA and Jefferies maintain positive ratings, citing strong growth momentum…

The Economic Times

Honasa Consumer Q4 results: Profit more than doubles to Rs 69 cr; co declares Rs 3 dividend

Honasa Consumer reported Q4 FY26 profit more than doubled to Rs 69 crore and record revenue of Rs 682 crore (28% YoY). Full-year PAT reached Rs 200 crore. Driven by stronger execution, offline expansion, and growth across core and younger brands, including new acquisition Reginald Men, the company declared a…

The Economic Times

Get all your
news in one place.

100's of premium titles.
One news app.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.